3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
56
Phase 1/2
23
Phase 1
12
Phase 3
11
Phase 4
2
Phase 2/3
2
Phase NA
1
Phase EARLY_PHASE1
1
Status
Withdrawn
2
Completed
2
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
6
pembrolizumab
5
Radiosurgery
5
Nivolumab
4
Fluorouracil
4
Carboplatin
4
Blood Specimen Collection
4
Biopsy
4
X-Rays
3
Vincristine
3
Surveys and Questionnaires
3
Proflavine
3
Positron-Emission Tomography
3
Metformin
3
Cisplatin
3
Bevacizumab
3
fludarabine phosphate
2
durvalumab
2
atezolizumab
2
Varenicline
2
Topotecan
2
Taxes
2
Specimen Handling
2
Rituximab
2
Radiotherapy
2
Positron Emission Tomography Computed Tomography
2
Oxaliplatin
2
Leucovorin
2
Letrozole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Terminated
×
Trastuzumab
×
Clear all
NCT04102618
2022-08-15
AWARE-1
Oncolytics Biotech
Phase EARLY_PHASE1
Terminated
26 enrolled